Alnylam Pharmaceuticals

  1. Home
  2. » Alnylam Pharmaceuticals

Based on Nobel Prize-winning science, Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases. Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a deep pipeline of investigational medicines, including five product candidates that are in late-stage development. Alnylam’s first RNAi therapeutic is Patisiran for hereditary ATTR (hATTR) amyloidosis, which is currently under Priority Review by Health Canada. Founded in 2002, Alnylam employs over 1000 people worldwide and is headquartered in Cambridge, Massachusetts, with Canadian headquarters in Mississauga, Ontario.